Nyxoah SA (NYXH) Earnings Call Transcripts
Nyxoah SA's Latest Earnings Call - May 14, 2026
In the Q1 2026 earnings call, Nyxoah SA reported revenue of EUR 6.4 million, reflecting a 13% growth quarter-over-quarter, with a notable 25% growth in the U.S. market. The company has transitioned from a clinical to a commercial stage, having treated over 1,200 patients and trained 207 surgeons in the U.S. Management raised guidance for Q2, projecting 25% to 30% growth compared to Q1, and an annual revenue target of EUR 36 million to EUR 40 million for the first year post-launch. This strong performance and positive outlook could drive stock momentum.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | EUR 6.4 million (beat) |
| U.S. Revenue | EUR 4.3 million (beat) |
| Annual Revenue Guidance | EUR 36 million to EUR 40 million (positive) |
| Gross Margin | 60% to 62% (positive) |
| Operating Expenses | EUR 97 million to EUR 99 million (null) |
| Surgeons Trained | 207 (positive) |
Guidance from management
Management provided guidance for Q2, projecting 25% to 30% growth compared to Q1, and an annual revenue target of EUR 36 million to EUR 40 million for the first year post-launch.
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape and potential reimbursement challenges in the U.S. market. There were questions about sustaining growth rates and the scalability of their commercialization strategy.
Main topics on the call
- Transition to Commercial Stage — Nyxoah has successfully transitioned from a clinical stage to a commercial stage company, with CEO Olivier Taelman stating, "we fully transitioned from a clinical stage company into a commercial stage company in the U.S....
- U.S. Market Growth — The U.S. market generated EUR 4.3 million, showing a robust 25% growth over Q4. Management noted, "we can speak about a successful first 6 months," indicating strong demand for their product.
- Surgeon Training and Market Penetration — Nyxoah trained 207 surgeons across 125 high-volume sites, with 91 active sites by the end of Q1. The CEO highlighted, "34 new accounts were activated in Q1," showcasing effective market penetration.
- Guidance Update — Management raised guidance for Q2, projecting 25% to 30% growth compared to Q1, with an annual revenue target of EUR 36 million to EUR 40 million. This is a strong indication of confidence in continued growth.
Read the full Nyxoah SA transcript (May 14, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Nyxoah SA
Nyxoah SA (NYXH) is a publicly listed company in the Health Care Equipment and Supplies industry, within the Health Care sector. It trades on ENXTBR and is based in BE. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 27 calls on record spanning March 17, 2021 to August 5, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 27 Nyxoah SA earnings call transcripts on record, spanning March 17, 2021 to August 5, 2026. Based on this history, Nyxoah SA reports quarterly. The most recent call on file is dated August 5, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- NYXH
- Exchange
- ENXTBR
- Country
- BE
- Sector
- Health Care
- Calls on record
- 27
- First call
- March 17, 2021
- Most recent
- August 5, 2026
- Reporting cadence
- quarterly